Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. ProQR Therapeutics NV's current 5-Year Share Buyback Ratio was -15.00%.
MEX:PRQRN's 5-Year Share Buyback Ratio is ranked worse than 61.29% of 1129
companies
in the Biotechnology industry
Industry Median: -10.2
vs MEX:PRQRN: -15.00
ProQR Therapeutics NV (MEX:PRQRN) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
ProQR Therapeutics NV 5-Year Share Buyback Ratio Related Terms
MEX:PRQRN vs NWBO, IMRX, VNDA: 5-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV 5-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's 5-Year Share Buyback Ratio falls into.
ProQR Therapeutics NV 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -15.00 mean?
ProQR Therapeutics NV (MEX:PRQRN) has a 5-Year Share Buyback Ratio of -15.00 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for ProQR Therapeutics NV and its competitors. According to the industry distribution chart, ProQR Therapeutics NV ranks #692 out of 1129 companies in the Biotechnology industry, placing it in the top 61.3%.
Is ProQR Therapeutics NV's 5-Year Share Buyback Ratio too high?
ProQR Therapeutics NV's current 5-Year Share Buyback Ratio is -15.00. Based on the distribution chart, ProQR Therapeutics NV ranks #692 out of 1129 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's 5-Year Share Buyback Ratio compare to NWBO and IMRX?
According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #692 out of 1129 companies for 5-Year Share Buyback Ratio. This places ProQR Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Biotechnology company?
A good 5-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current 5-Year Share Buyback Ratio is -15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current 5-Year Share Buyback Ratio of -15.00. The stock's GF Value™ is MXN37.10, compared to a current price of MXN36.00 — trading 3% below its estimated fair value. The current 5-Year Share Buyback Ratio is -15.00. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current 5-Year Share Buyback Ratio is -15.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of MXN36.00 is trading 3% below its estimated GF Value™ of MXN37.10.
Key valuation signals for MEX:PRQRN:
5-Year Share Buyback Ratio: -15.00
GF Value™: MXN37.10 vs. price of MXN36.00 (3% below fair value)
No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score
Get the complete analysis for MEX:PRQRN
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRQRN has been successfully added to your 
